After 3 months under treatment with DPP-4 inhibitors, blood glucose level reduced by 1.72 ± 2.01 mmol / L, HbA1c reduced by 1.08 ± 0.82% on average; 37.9% and 35.8% of the study population achieved blood glucose goal and HbA1c goal, respectively.